Header Logo

Connection

NANBING LI-VILLARREAL to Receptor, ErbB-2

Back to Details
This is a "connection" page, showing publications NANBING LI-VILLARREAL has written about Receptor, ErbB-2.
NANBING LI-VILLARREAL
Connection Strength
0.028
Receptor, ErbB-2
  1. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.